Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant [Phase 3]
Phase 3 trial comparing pixantrone + rituximab versus gemcitabine + rituximab in aggressive B-cell non-Hodgkin lymphoma and follicular grade…
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab plus CHOP with sargramostim in newly diagnosed diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-11-08Clinical Trial Update: Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating zanubrutinib in participants with relapsed/refractory non-GCB type diffuse large B-cell lymphoma has completed, w…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]
Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma [Phase 2]
Phase II trial update for dose-adjusted EPOCH-Rrituximab in adults with untreated Burkitt lymphoma and c-MYC positive diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2021-10-13Clinical Trial Update: Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 trial update for idelalisib in relapsed diffuse large B-cell lymphoma has completed enrollment.
-
CLINICAL_TRIALS trial_result · 2021-10-08Clinical Trial Update: Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line [Phase 3]
Phase 3 trial update evaluating an APA program's impact on event-free survival in first-line diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL [Phase 3]
A Phase 3 trial evaluates intermediate-dose intravenous methotrexate as central nervous system prophylaxis for high-risk diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2021-09-20Clinical Trial Update: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL [Phase 2]
Phase II trial update examining tirelizumab with the R2-ICE regimen for relapsed/refractory diffuse large B-cell lymphoma and high-grade B-c…
-
CLINICAL_TRIALS trial_result · 2021-09-10Clinical Trial Update: A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients [Phase 3]
Phase 3 trial comparing H-CHOP versus R-CHOP in untreated CD20-positive diffuse large B-cell lymphoma; status and full results not yet avail…
-
CLINICAL_TRIALS trial_result · 2021-08-20Clinical Trial Update: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma [Phase 1]
Phase 1 study evaluating a combination of carfilzomib, rituximab, ifosfamide, carboplatin, and etoposide in relapsed or refractory stage I-I…
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） [Phase 2]
Phase 2 clinical trial update for TQ-B3525 in relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib with rituximab for relapsed/refractory DLBCL with MYD88 and CD79A/B mutations after at…
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating loncastuximab tesirine for relapsed or refractory diffuse large B-cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A phase 1/2 trial investigating obinutuzumab with idasanutlin and venetoclax in relapsed/refractory follicular lymphoma and rituximab with i…
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP [Phase 3]
Phase 3 trial comparing lenalidomide maintenance to placebo in responding elderly patients with diffuse large B-cell lymphoma treated with R…
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating S1001 PET-directed therapy for limited-stage diffuse large B-cell lymphoma has completed; results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: 18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
A completed clinical trial investigating 18F-FDG PET radiomics in diffuse large B-cell lymphoma, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant [Phase 2]
Phase 2 trial of ruxolitinib phosphate for recurrent/ refractory diffuse large B-cell lymphoma and mature T-/NK-cell non-Hodgkin lymphoma af…
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and efficacy of Bendamustine, Gemcitabine, Rituximab, and Nivolumab (BeGeRN) in relapsed/refractory diffuse…
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab with standard chemotherapy, with or without lenalidomide, in adults with newly diagnosed Stage II-IV di…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating high-dose Y-90 ibritumomab tiuxetan added to reduced-intensity allogeneic stem cell transplant for relapsed or refr…